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ABSTRACT
Biomarker changes between primary (PT) and metastatic tumor (MT) site may 
be significant in individualizing treatment strategies and can result from actual clonal 
evolution, biomarker conversion, or technical limitations of diagnostic tests. 
This study explored biomarker conversion during breast cancer (BC) progression 
in 67 patients with different tumor subtypes and metastatic sites via mRNA 
quantification and subsequently analyzed the concordance between real-time qPCR 
and immunohistochemistry (IHC). Immunostaining for estrogen receptor (ER), 
progesterone receptor (PR), HER2, and Ki-67 was performed on formalin-fixed, paraffin-
embedded PT and MT tissue sections. RT-qPCR was performed using a multiplex RT-
qPCR kit for ESR1, PGR, ERBB2, and MKI67   and the reference genes B2M and CALM2.
Subsequent measurement of tumor biomarker mRNA expression to detect 
conversion revealed significant decreases in ESR1 and PGR mRNA and MKI67 
upregulation (all p < 0.001) in MT compared to PT of all tumor subtypes and ERBB2 
upregulation in MT from triple-negative PT patients (p = 0.023). Furthermore, ERBB2 
mRNA was upregulated in MT brain biopsies, particularly those from triple-negative PTs 
(p = 0.023). High concordance between RT-qPCR and IHC was observed for ER/ESR1 
(81%(κ 0.51) in PT and 84%(κ 0.34) in MT, PR/PGR (70%(κ 0.10) in PT and 78% 
(κ −0.32) in MT), and for HER2/ERBB2 (100% in PT and 89% in MT). Discordance 
between mRNA biomarker assessments of PT and MT resulting from receptor 
conversion calls for dynamic monitoring of BC tumor biomarkers. Overall, RT-qPCR 
assessment of BC target genes and their mRNA expression is highly concordant with 
IHC protein analysis in both primary and metastatic tumor.
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INTRODUCTION 
Tremendous progress has been made in the 
treatment of metastatic breast cancer (MBC) in recent 
decades, but still very few therapies use patient or tumor-
specific characteristics to tailor individualized treatment 
[1, 2]. Breast cancer (BC) is a disease with heterogeneous 
tumor biology, comprising divergent molecular subtypes 
[3–5]. In this context, one of the main challenges is to 
minimize overtreatment by developing precise patient 
selection criteria for targeted therapies by defining new 
biomarkers or real-time monitoring of tumor biology 
dynamics and minimal residual disease (MRD) [1, 6].
Clinical decision making in both primary and MBC 
is based on pathologic assessment of tumor biomarkers, 
preferably target genes or proteins acquired from primary 
tumor biopsy.
There is a growing body of evidence describing 
tumor biomarker conversion, i.e. upregulation or 
downregulation of hormone receptors, HER2/ERBB2 and 
Ki-67/MKI67 when comparing metastatic tumors (MT) 
with primary tumors (PT) [7–19]. The ability to capture 
tumor biomarker changes in the course of BC progression 
could have consequences for further diagnostic 
procedures, in the context of liquid biopsies [20, 21] or 
conventional rebiopsies [22, 23], as well as potential 
therapeutic implications, especially for trials aiming 
for an extended indication of HER2 targeted therapies. 
Conventional rebiopsies upon reaching the next stage of 
cancer progression are a suboptimal method due to their 
limited feasibility and invasiveness. 
Identifying associations between immunophenotype 
and patterns of the metastatic spread of BC could help 
define surrogate markers to identify patients with a 
high risk for developing cerebral metastases based on 
tumor biomarker status at the time of primary diagnosis. 
Therefore, reliable and sensitive methods of quantifying 
changes in target tumor biomarker expression in the 
course of cancer progression are of utmost importance for 
optimizing treatment strategies in the metastatic situation.
Apart from substantial biomarker conversion at 
the mRNA/protein level or even clonal evolution as 
genetic alterations – mainly hotspot mutations [24–29], 
another potential scenario behind the conversion of tumor 
biomarker is due to technical limitations of dichotomous 
biomarker assessment via conventional IHC. Exact 
quantification of the underlying target gene and protein 
expression could essentially facilitate exploration of tumor 
biomarker conversion upon disease progression, and 
therefore the present study used a highly standardized real-
time quantitative polymerase chain reaction (RT-qPCR) 
kit to compare the expression levels of the ESR1, PGR, 
ERBB2, and MKI67 genes in matched pairs of BC PT and 
MT samples. In addition, matched results from conventional 
immunohistochemistry assessments of the same biomarkers 
were compared to address the concordance or discordance 
between the mRNA and protein assessments. 
The study objective was to use mRNA quantification 
to explore biomarker conversion in different tumor 
subtypes and metastatic locations during breast cancer 
progression and to analyze the concordance between RT-
qPCR and IHC in PT and MT samples.
RESULTS 
Matched BC PT and MT samples were available 
from 67 patients. Median age at the time of primary BC 
diagnosis was 51.9 years. Median age at first diagnosis of 
metastatic disease was 56.9 years. As shown in Table 1, 
patients with the luminal subtype (hormone receptor 
positive, HER2 negative as assessed by IHC of the PT) 
comprised 62% of the total cohort. 
This study initially compared the dynamics of tumor 
biomarkers in PTs vs. MTs by biopsy site using RT-qPCR. 
The mRNA assessment showed ESR1 downregulation 
in MT (compared to PT) samples from all biopsy sites, 
the difference being statistically significant in the brain 
(40−∆∆CT p < 0.001). PGR was downregulated in 
MT (vs. PT) from all biopsy sites, the difference being 
significant in the brain (40−∆∆CT p < 0.001), liver 
(40−∆∆CT p = 0.004), and skin/soft tissue samples 
(40−∆∆CT p = 0.006). MKI67 was upregulated in MT 
(vs. PT) in samples from all biopsy sites, the difference 
being significant in the brain (40−∆∆CT p = 0.034), bone 
(40−∆∆CT p < 0.001), and skin/soft tissue (40−∆∆CT 
p = 0.018). Furthermore, a modest ERBB2 upregulation 
trend in MT (vs. PT) was recorded in patients with MT in 
biopsies from the brain (40−∆∆CT p = 0.138) and bone 
(40−∆∆CT p = 0.138), see Figure 1. 
Subsequently, changes in tumor biomarker mRNA 
expression were measured in MT compared to the PT 
baseline for each phenotype. Significant decreases in 
ESR1 and PGR mRNA and upregulation of MKI67 (all 
p < 0.001) were observed in MT vs. PT of all phenotypes 
(Figure 2A). ERBB2 upregulation was significant in MT 
from triple-negative vs. non-triple-negative PT patients 
(p = 0.023, Mann–Whitney U Test), as shown in Figure 2B. 
An adjacent analysis focused on the dynamics of tumor 
biomarker mRNA expression by tumor subtype in MT vs. 
PT samples from particular metastatic sites. 
Brain metastasis
ESR1/PGR expression was significantly 
downregulated (p < 0.001) in brain MT biopsies for all 
tumor subtypes (compared to PT), while ERBB2 mRNA 
was upregulated in brain MT biopsies, particularly in 
triple-negative PTs (p = 0.023), as shown in Figure 3. 
Bone metastasis
Accordingly, the study assessed the conversion 
of tumor biomarkers in MT vs. PT baseline by 
immunophenotype in bone-acquired biopsies using RT-
Oncotarget3www.impactjournals.com/oncotarget
qPCR. ESR1 and PGR expression levels were modestly 
downregulated in bone MT compared to PT biopsies 
for all immunophenotypes (p = 0.177 and p = 0.138, 
respectively), while ERBB2 mRNA was upregulated in 
bone MT biopsies, particularly in triple-negative PTs 
(p = 0.138), as shown in Figure 4. 
Concordance 
For each biomarker, we calculated the concordance 
between the RT-qPCR result and the hormone and 
HER2 status as established by IHC and obtained from 
diagnostic pathology reports. High concordance between 
Table 1: Clinicopathological patient characteristics
Patient characteristic                                           n (%)
Total, n 67
Median age at PT biopsy, years 51,9
Median age at MT biopsy, years 56,9
Phenotype of primary tumor by IHC, n (%)
   Luminal A 25 (37%)
   Luminal B (HER2-negative) 15 (22%)
   Luminal B (HER2-positive) 2 (3%)
   HER2 positive (non-luminal) 6 (9%)
   Triple-negative 17 (25%)
   NA 2 (3%)
Grading of primary tumor, n (%)
G1
   G1 0 (0%)
   G2 40 (60%)
   G3 20 (30%)
   GX 7 (10%)
ER/ESR1 status of primary tumor, n (%) IHC RTqPCR
   Positive 44 (66%) 42 (63%)
   Negative 23 (34%) 24 (36%)
   Unknown 0 (0%) 1 (2%)
PR/PGR status of primary tumor, n (%)
   Positive 42 (63%) 29 (43%)
   Negative 25 (37%) 37 (55%)
   Unknown 0 (0%) 1 (2%)
HER2/ERBB2 status of primary tumor, n (%)
   Positive 14 (21%) 8 (12%)
   Negative 39 (58%) 58 (87%)
   Unknown 14 (21%) 1 (2%)
Site of metastatic biopsy, n (%)
   Bone 24 (36%)
   Brain 19 (28%
   Liver 8 (12%)
   Lung 2 (3%)
   Pleura 3 (5%)
   Soft tissue 11 (16%)
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RT-qPCR and IHC assessments was observed for ER/
ESR1: 81% (κ 0.51) in PT and 84% (κ 0.34) in MT; PR/
PGR: 70% (κ 0.10) in PT and 78% (κ −0.32) in MT; 
and HER2/ERBB2: 100% in PT and 89% in MT, see 
Table 2. As regards the recognition of discordance in 
receptor conversion, three patients showed a change from 
ER-negative PT to ER-positive MT as assessed by RT-
qPCR. These biopsies were obtained from one lung MT 
and two bone MTs. IHC showed that in four patients a 
“non-luminal” PT converted to a “luminal” MT exhibiting 
hormone receptor expression, while only one such case 
was observed with RT-qPCR.
DISCUSSION
Biomarker conversion: ERBB2 overexpression 
in initially HER2 negative metastatic breast 
cancer 
Recently, a growing body of evidence has emerged, 
confirming that a shift in hormone receptor status from 
positive in PT to negative in MT is associated with worse 
survival compared with consistent endocrine sensitivity. 
Hormone receptors have been shown to be independent 
prognostic factors for post-recurrence BC mortality in 
multivariate analyses at all stages of tumor progression 
[23, 30–32]. Our analysis was able to confirm a tendency 
in biomarker conversion towards a more aggressive 
phenotype with significant downregulation of ESR1 and 
PGR in biopsies from all MT sites and in all molecular 
subtypes of MT, as well as a boost in the proliferation 
marker MKI67 in all phenotypes (p < 0.001). 
Apart from the expected downregulation of 
hormone receptors and upregulation of Ki-67 in all tumor 
subtypes of MT compared to PT, ERBB2 upregulation 
was observed in MT samples from triple-negative PT 
patients (p = 0.292), whereas ERBB2 overexpression was 
particularly significant in brain MTs in initially triple-
negative PT BC (p = 0.023). Other trials comparing 
HER2 PT and MT status have evidenced HER2 receptor 
dynamics [22, 33–36], but the present study is one of 
the first to demonstrate significantly increased HER2 
levels in cerebral entities originating from triple-negative 
BC PTs [37–40].
Figure 1: mRNA assessment of tumor biomarkers in metastatic tumor (MT) vs. primary (PT) tumor samples, by 
biopsy site.
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Diagnostic potential for liquid biopsy and 
rebiopsy, and the therapeutic consequences
The discordances between PT and MT mRNA 
biomarker assessments caused by receptor conversion call 
for dynamic monitoring of BC tumor biomarkers, preferably 
via liquid biopsy or via rebiopsy of metastatic lesions, 
based on soluble receptors or receptor MRD status, i.e. 
disseminated tumor cells (DTCs) or circulating tumor cells 
(CTCs) as precursors of metastatic lesions [20, 21, 41–43]. 
The presence of CTCs in peripheral blood is a known 
independent predictor of poor progression free survival 
(PFS) and overall survival (OS) in MBC [20, 44–47].
Further clinical studies are required to analyze the 
potential benefit of extending the indication for HER2-
targeted therapies, for example, for brain-metastasized 
patients with initially triple-negative BC PTs, either via 
dual blockade by trastuzumab/pertuzumab or via agents 
such as T-DM1, which was shown to be superior in the 
EMILIA study [48, 49], or possibly lapatinib, a dual 
tyrosine kinase inhibitor that interferes with both the 
epidermal growth factor receptor (EGFR) and HER2 
signaling pathways. A recently developed murine model 
suggests improved anti-tumor efficacy with lapatinib-
loaded human serum albumin nanoparticles in triple-
negative BC metastasis to the brain [50].
Determination of HER2 status of CTCs may help 
to optimize individualized treatment solutions, especially 
in the case of metastatic sites which are unavailable or 
suboptimal for rebiopsy. Moreover, HER2-CTC positivity 
in patients with initially triple-negative PT could serve 
as an additional criterion to perform cerebral imaging 
earlier, before the onset of severe neurological symptoms. 
In this context, the DETECT Study group has addressed 
the value of CTC HER2 overexpression in predicting the 
HER2 status of metastases. However, they were unable to 
demonstrate any significant change in HER2 expression 
between PT and MT [51]. 
Concordance of RT-qPCR and IHC in assessing 
tumor biomarkers in the PT and MT settings
In our study, assessments of BC biomarkers and 
their dynamics from PT to MT showed a high degree 
of concordance between mRNA quantification with the 
well-established IHC methodology, the gold standard in 
immunophenotyping.
As shown in Table 2, the concordance of these two 
methodologies was 81% (κ 0.51) in PT vs. 84% (κ 0.34) 
in MT for ER/ESR1; 70% (κ 0.10) in PT vs. 78% (κ −0.32) 
in MT for PR/PGR; and 100% in PT vs. 89% in MT for 
HER2/ERBB2. These concordance rates are consistent 
with multiple recent prospective-retrospective studies 
using a similar mRNA quantification methodology. Both 
the FinHer and the S080 trial reported concordance rates 
> 90% between RT-qPCR and image-based IHC [52].
Table 2: (A) Concordance calculation between RT-qPCR and IHC for the biomarkers studied, (B) 
Methodologic discrepancies in receptor conversion recognition
a) Concordance of RT-qPCR and IHC ER/ESR1 PR/PGR
Primary breast cancer (PT) 81%     κ 0.51 70%     κ 0.10
Metastatic breast cancer (MT) 84%     κ 0.34 78%     κ−0.32
b) Hormone receptor conversion RT-qPCR IHC
Total: 19 (20)*/55° 21 (22)*/53†
Both neg to both pos 0 1
Both pos to both neg 4 4
ER neg to pos/PR neg 1 1
ER neg to pos/PR pos 1 3
ER pos to neg/PR neg 2 0
ER pos to neg/PR pos 1 1
PR neg to pos/ER neg (1)* 1
PR neg to pos/ER pos 0 1
PR pos to neg/ER neg 0 1
PR pos to neg/ER pos 8 8 (9)*
* One patient had 2 MT biopsies for one PT, but only one MT biopsy showed a shift, thus the value including the shifting 
sample in brackets.
° RT-qPCR total comprises 55 patients as % tumor cells were insufficient for accurate statement of hormone receptor 
positivity/negativity in 11 MT and 1 PT.
†IHC total comprises 53 samples as immunohistochemistry was missing for 14 samples.
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Figure 2: Changes from PT baseline in the MT mRNA levels of tumor biomarkers, by tumor subtype. (A) 40−ΔΔ Cq; 
(B) Mann–Whitney test. 
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Several methodological limitations to measuring 
biomarker changes as reported here warrant discussion. 
On the one hand, the feasibility of rebiopsies, especially 
before each new therapy line, is limited at various 
metastatic sites. On the other hand, tumor heterogeneity 
both within the PT and the MT sites [40] as well as 
between these two entities and the surrogate markers of 
MRD, foremost the CTCs, present further limitations. 
Another limitation to our findings arises from the 
structure of our patient population, which was a series 
of cases rather than a representative general population 
sample. The relatively young age at primary diagnosis can 
be explained by the large number of triple-negative cases 
(25%) and brain metastases (28%).
CONCLUSIONS
We observed a tendency in biomarker conversion 
towards a more aggressive phenotype with significant 
downregulation of ESR1 and PGR in biopsies from 
all MT sites and in all molecular subtypes of MT, as 
well as a boost in the proliferation marker MKI67 in 
all phenotypes (p < 0.001) The discordance in mRNA 
biomarker assessment between PT and MT due to receptor 
conversion necessitates dynamic monitoring of tumor 
biomarkers, possibly via liquid biopsy, e.g. circulating 
tumor cells (CTCs), or rebiopsy of metastatic lesions. 
In patients with initially triple-negative PTs, 
detection of increased HER2 levels in the MT biopsy 
correlates significantly with brain and bone metastatic 
progression. To the best of our knowledge, this study is 
one of the first so far to imply the correlation of HER2 
overexpression in initially triple-negative BC and brain 
metastasis. This tendency could be caused by substantial 
HER2/ERBB2 upregulation or clonal progression in the 
course of the BC metastatic process. In this context, 
robust real-time HER2 monitoring of CTC-HER2 may, 
hypothetically, predict metastasis to brain or bone and 
affect diagnostic and therapeutic decision making. 
Determining the HER2 status of CTCs might help to 
optimize individualized treatment solutions, especially 
in the case of metastatic sites which are unavailable or 
suboptimal for rebiopsy. 
Overall, RT-qPCR assessment of breast cancer target 
genes and their mRNA expression is methodologically 
highly concordant with IHC protein analysis of the tumor 
Figure 3: Changes from PT baseline in brain MT mRNA levels of tumor biomarkers, by tumor subtype.
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biology of both PTs and MTs, further supporting multiple 
recent prospective-retrospective studies based on similar 
mRNA quantification methodology. The hypothesis-
generating nature of the findings from the present study 
calls for additional studies in order to comprehensively 
establish and broaden the evidence base for this technique.
MATERIALS AND METHODS
Patients
The patient cohort was selected by screening the 
tumor banks of two institutions (Heidelberg University 
Hospital, Heidelberg, Germany and Zurich University 
Hospital, Zurich, Switzerland) for formalin-fixed, paraffin-
embedded (FFPE) matched pairs of primary and metastatic 
BC tissue samples. 
Patients were enrolled in the study from April 2011 
through May 2015. The inclusion criterion was enrollment 
in MBC studies in Heidelberg or Zurich with the 
availability of matched pair samples of the primary breast 
tumor and an appropriate metastatic biopsy, irrespective of 
age at initial diagnosis or metastatic entity.
This study was a part of a previously approved 
breast cancer project at the University of Zurich, ethics 
approval no. KEK-2012-553. Ethical approval for the 
cohort from Heidelberg was obtained from the Ethics 
Committee of the Medical Faculty of the University of 
Heidelberg, approval no. S-295/2009.
Immunohistochemistry (IHC)
Conventional immunostaining of sections of FFPE 
primary and metastatic tumor tissue for ER, PR, HER2, 
and Ki-67 was performed at the pathology laboratories of 
the two study sites according to their local standard 
procedures for ER (clone 1D5), PR (clone PgR636), and 
HER2 (A0485) in both PT and MT tissue. 
ER and PR results were considered positive if at 
least 10% of cancer cells stained positive. This cut-off 
was chosen for two reasons: (1) to be able to distinguish 
more clearly between hormone-receptor positivity and 
negativity and (2) because low ER+/HER2− tumors have 
been shown to be more similar to triple-negative tumors 
than the usual type of ER+ tumors, and are not clearly 
endocrine responsive [53].
Figure 4: Changes from PT baseline in bone MT mRNA levels of tumor biomarkers, by tumor subtype.
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Ki-67 assays were analyzed by determining the 
proportion of positively stained relative to all cancer cell 
nuclei in the tissue section, expressed as a percentage 
between 0 and 100%. Pathologists at the respective 
institution interpreted the ER, PR, HER2, and Ki-67 
immunostaining results in accordance with local standard 
practice.
Chromogenic in situ hybridization (CISH)
Tumors with a score of 2+ or 3+ (on a scale from 0 
to 3+) for HER2 expression as determined by IHC were 
further analyzed for HER2 gene amplification by CISH 
in one of two central laboratories. The HER2 status was 
considered positive if six or more gene copies per nucleus 
were present. HER2 status was considered positive if 
CISH for HER2 was positive, and negative if CISH 
was negative, regardless of the degree of HER2 protein 
expression as determined by IHC [52].
Real time qPCR (RT-qPCR)
RNA was extracted using a bead-based extraction 
method (RNXtract® IVD kits, BioNTech Diagnostics 
GmbH, Mainz, Germany). Multiplex RT-qPCR utilized 
MammaTyper IVD® kits for ESR1/PGR/ERBB2 and 
MKI67 (BioNTech Diagnostics GmbH). After pathology 
confirmed that tissue sections were representative for 
the presence of cancer, a single whole-face 10-μm-thick 
slice from each FFPE tumor block was processed with the 
RNXtract® RNA extraction kit (BioNTech Diagnostics 
GmbH) using a magnetic particle-based assay, according 
to previously established protocols [52]. RT-qPCR was 
performed using the MammaTyper® kit (BioNTech 
Diagnostics GmbH) for ESR1, PGR, ERBB2, and MKI67, 
and the two reference genes B2M and CALM2, on a 
Versant® kPCR system (Siemens, Erlangen, Germany). 
This involved applying one cycle of primer-specific 
reverse transcription followed by 40 cycles of nucleic 
acid amplification [52,54]. The median quantification 
cycles (Cq) for each of the four genes of interest (GOI) 
were normalized against the two reference genes (REF) 
and presented as ΔΔCq values relative to the positive 
control, obtained after subtracting the ΔCq value of the 
positive control (pc) from the ΔCq of the sample (s) by 
the formula: 40−ΔΔCq(GOI)s = 40 − ((Cq[GOI]s − mean 
Cq[REF]s) − (Cq[GOI]pc − mean Cq[REF]pc)).
Sensitivity studies as previously reported [55] were 
performed to exclude the major influence of varying tumor 
cell content for assay results. A number of cases with 
particularly low levels of invasive carcinoma and varying 
amounts of ductal carcinoma in situ were analyzed before 
and after macrodissection, subsequently confirming that 
tumor cell content did not influence the final test result. 
This enabled the exclusion of any major influence of 
tumor cell content (TCC) on ERBB2, ESR1, PGR, and 
MKI67 mRNA expression. 
Definition of breast cancer biological subtypes
After identifying each of the four biomarkers 
as positive or negative, the molecular subtype of each 
tumor was determined using the currently proposed 
IHC-based breast cancer molecular subtyping algorithm 
[56]. In concordance with previous studies using mRNA 
phenotype assessment [52], luminal A cancers were 
defined as having a high ESR1 or PGR mRNA content 
and a low ERBB2 and MKI67 content. Luminal B cancers 
were defined as having high cancer and MKI67 content, 
or high ESR1 content but low PGR and ERBB2 content. 
Triple-negative cancers comprised those cancers that had 
low ESR1, PGR and ERBB2 mRNA content, irrespective 
of cancer MKI67 mRNA content.
The same scheme was used to categorize the cancers 
according to the IHC and CISH results, but using protein 
expression (at IHC) and the number of HER2 gene copies 
(at CISH) instead of cancer mRNA content. For example, 
cancers that were ER and PR positive (with ≥10% of 
nuclei positive in each staining) and HER2 negative 
(by CISH), and had low Ki-67 (<20% of nuclei staining 
positive at IHC) were considered luminal A cancers. This 
cut-off was chosen based on our own cases and Ki-67 
staining results [57] as well as the cut-off from the 2013 
St. Gallen consensus [56].
Statistical methods
To analyze and compare quantitative RT-qPCR 
marker levels, this study explored the changes during 
tumor progression (by subtype), location, and time 
interval. RT-qPCR and IHC results were compared 
between paired primary and metastatic sites. RNA levels 
were normalized according to the 40−ΔΔCq method. 
Changes in RNA marker levels were analyzed qualitatively 
and quantitatively to visualize specific biomarker profiles 
based on tumor subtype, metastatic site, and time between 
PT and MT biopsy.
Demographic data and clinical characteristics were 
described as frequency and percentage, median and range, 
or mean and standard deviation. Groups were compared 
using the Wilcoxon/Mann–Whitney rank test or Fisher’s 
exact test, as appropriate. A significance level of 5% was 
chosen.
Abbreviations 
BC: breast cancer; MBC: metastatic breast 
cancer; PT: primary tumor; MT: metastatic tumor; 
DTCs: disseminated tumor cells; CTCs: circulating 
tumor cells; ER: estrogen receptor; PR: progesterone 
receptor; HER2: human epidermal growth factor receptor 
2; CISH: Chromogenic in situ hybridization; ESR1: 
Estrogen Receptor 1 gene; PGR: Progesterone Receptor 
gene; ERBB2: Receptor tyrosine-protein kinase erbB-2 
gene; IHC: immunohistochemistry; RT-qPCR: real-time 
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quantitative polymerase chain reaction; EGFR: epidermal 
growth factor receptor; TCC: tumor cell content; MRD: 
minimal residual disease.
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